siRNA Knocking Down in HepG2 Cells Identifies PFKFB4 and HNF4α as Key Genes Important for Cancer Cell Survival

Area of Science:

• Biotechnology
• Molecular Biology
• Nanomedicine

Background:

• Liposomes are effective carriers for small interfering RNAs (siRNAs), improving cellular uptake and gene silencing.
• Hepatic carcinoma treatment requires efficient delivery of therapeutic agents like siRNAs.
• This study evaluates a novel liposome formulation against a commercial standard for siRNA delivery.

Purpose of the Study:

• To compare the efficacy of a new liposome formulation with lipofectamine for delivering siRNAs targeting HNF4-α and PFKFB4 in hepatic carcinoma cells.
• To assess the cellular uptake, gene silencing efficiency, and cytotoxicity of the liposome-mediated siRNA delivery system.

Main Methods:

• Flow cytometry and confocal microscopy were used to evaluate the internalization of lipoplexes in HepG2 cells.
• Cytotoxicity assays were performed to determine the impact of siRNA-loaded liposomes on cell viability.
• Real-time PCR was employed to quantify the reduction in target gene mRNA expression (HNF4-α and PFKFB4).

Main Results:

• The new liposome formulation demonstrated significantly higher cytotoxicity (93% at 100 nM) compared to lipofectamine (50% at 100 nM).
• Liposome-encapsulated siHNF4-α reduced HNF4-α mRNA by tenfold at 100 nM, outperforming lipofectamine's twofold reduction at 200 nM.
• siPFKFB4 delivered via liposomes achieved a dose-dependent 35-fold reduction in PFKFB4 mRNA at 100 nM, exceeding lipofectamine's efficacy.

Conclusions:

• The novel liposome formulation shows superior performance in delivering siRNAs for gene silencing in hepatic carcinoma models.
• Enhanced cellular uptake and gene silencing efficiency position this liposome formula as a promising candidate for targeted gene therapy.
• Further investigation into in vivo biodistribution and combination therapies is warranted.